Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 14;122(7):367-374.
doi: 10.1515/jom-2021-0163.

Review of medication-assisted treatment for opioid use disorder

Nessreen Ghanem  1 , Devin Dromgoole  1 , Ahmad Hussein  1 , Richard T Jermyn  1
Affiliations
Free article
Review

Review of medication-assisted treatment for opioid use disorder

Nessreen Ghanem et al. J Osteopath Med. .
Free article

Abstract

Context: The American opioid epidemic has necessitated the search for safe and effective means of treatment for opioid use disorder (OUD). Medication-assisted treatment (MAT) encompasses select medications that are proven effective treatments for OUD. Understanding the mechanisms of action, indications, and implementation of MAT is paramount to increasing its availability to all individuals struggling with opioid addiction.

Objectives: This review is based on an educational series that aims to educate healthcare providers and ancillary healthcare members on the use of MAT for the treatment of OUD.

Methods: The database PubMed was utilized to retrieve articles discussing the implementation of MAT. Boolean operators and Medical Subject Headings (MeSHs) were applied including: MAT and primary care, MAT and telehealth, methadone, buprenorphine, naltrexone, MAT and osteopathic, MAT and group therapy, and MAT and COVID-19.

Results: Three medications have been approved for the treatment of OUD: methadone, naltrexone, and buprenorphine. Identifying ways to better treat and manage OUD and to combat stigmatization are paramount to dismantling barriers that have made treatment less accessible. Studies suggest that primary care providers are well positioned to provide MAT to their patients, particularly in rural settings. However, no study has compared outcomes of different MAT models of care, and more research is required to guide future efforts in expanding the role of MAT in primary care settings.

Conclusions: The coronavirus disease 2019 (COVID-19) pandemic has led to changes in the way MAT care is managed. Patients require a novel point-of-care approach to obtain care. This review will define the components of MAT, consider the impact of MAT in the primary care setting, and identify barriers to effective MAT. Increasing the availability of MAT treatment will allow for greater access to comprehensive treatment and will set the standard for accessibility of novel OUD treatment in the future.

Keywords: OUD; medication-assisted treatment; opioid use disorder.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cole, ES, DiDomenico, E, Cochran, G, Gordon, AJ, Gellad, WF, Pringle, J, et al.. The role of primary care in improving access to medication-assisted treatment for rural Medicaid enrollees with opioid use disorder. J Gen Intern Med 2019;34:936–43, https://doi.org/10.1007/s11606-019-04943-6.
    1. US Department of Health and Human Services. What is the U.S. opioid epidemic? HHS Gov; 2021. Available from: https://www.hhs.gov/opioids/about-the epidemic/index.html [Accessed 7 Jan 2022].
    1. Center for Disease Control and Prevention. Opioid data analysis and resources. Department of Health and Human Service; 2020. Available from: https://www.cdc.gov/opioids/data/analysis-resources.html [Accessed 7 Jan 2022].
    1. Harringa, A. Emergency department visits related to opioid overdoses up significantly during COVID-19 pandemic. Mayo Clinic; 2021. Available from: https://newsnetwork.mayoclinic.org/discussion/emergency-department-visit... [Accessed 7 Jan 2022].
    1. Luo, F, Li, M, Florence, C. State-level economic costs of opioid use disorder and fatal opioid overdose — United States, 2017. MMWR Surveill Summ 2021;70. https://doi.org/10.15585/mmwr.mm7015a1.

MeSH terms

LinkOut - more resources